- The primary use of stimulants such as
methylphenidate (Ritalin) is the treatment of
children with ADHD. Methylphenidate has
been proven to be successful in allowing these
children to slow down their activity and focus
on the tasks at hand and their schoolwork.
Its exact mechanism of action is unknown. - Clients from various cultures may metabolize
medications at different rates and, therefore,
require alterations in standard dosages. - Assessing use of herbal preparations is essen-
tial for all clients.
For further learning, visit http://connection.lww.com.
REFERENCES
Allison, D. B., & Casey, D. E. (2001). Antipsychotic-induced
weight gain: A review of the literature. Journal of
Clinical Psychiatry, 62(suppl. 7), 22–31.
American Psychiatric Association. (2000). Diagnostic and
statistical manual of mental disorders (4th ed., text
revision). Washington, DC: Author.
Beaubrun, G., & Gray, G. E. (2000). A review of herbal
medicines for psychiatric disorders. Psychiatric Ser-
vices, 51(9), 1130–1134.
Casey, D. E., & Zorn, S. H. (2001). The pharmacology of
weight gain with antipsychotics. Journal of Clinical
Psychiatry, 62(suppl. 7), 4–10.
Egan, M. F., & Hyde, T. M. (2000). Schizophrenia: Neuro-
biology. In B. J. Sadock & V. A. Sadock (Eds.), Com-
prehensive textbook of psychiatry,Vol. 1. (7th ed.,
pp. 1129–1147). Philadelphia: Lippincott Williams &
Wilkins.
Gray, R. (2001). Medication-related cardiac risks and
sudden deaths among people receiving antipsychotics
for the first time. Mental Health Care, 4(3), 301–304.
Gray, R., & Gournay, K. (2001). What can we do about ex-
trapyramidal symptoms? Journal of Psychiatric and
Mental Health Nursing, 7,205–211.
Green, A. I., Patel, J. K., Goisman, R. M., Allison, D. B.,
& Blackburn, G. (2000). Weight gain from novel anti-
psychotic drugs: Need for action. General Hospital
Psychiatry, 22,224–235.
Karson, C. N., & Renshaw, P. F. (2000). Principles of
neuroimaging: Resonance techniques. In B. J. Sadock
& V. A. Sadock (Eds.), Comprehensive textbook of
psychiatry, Vol. 1(7th ed., pp. 162–172). Philadelphia:
Lippincott Williams & Wilkins.
Keck, P. E., McElroy, S. L., & Arnold, L. M. (2001).
Ziprasidone: A new atypical antipsychotic. Expert
Opinions in Pharmacotherapy, 2(6), 1033–1042.
Kudzma, E. C. (1999). Culturally competent drug admin-
istration. American Journal of Nursing, 99(8), 46–52.
Lawson, W. B. (1996). The art and science of psycho-
pharmacology of African Americans. Mt. Sinai Journal
of Medicine, 63(5–6), 301–305.
Lewis, D. A. (2000). Functional neuroanatomy. In B. J.
Sadock & V. A. Sadock (Eds.), Comprehensive text-
book of psychiatry, Vol. 1(7th ed., pp. 3–31).
Philadelphia: Lippincott Williams & Wilkins.
Malison, R. T., & Innis, R. B. (2000). Principles of neuro-
imaging: Radiotracer techniques. In B. J. Sadock &
V. A. Sadock (Eds.), Comprehensive textbook of psy-
chiatry, Vol. 1(7th ed., pp. 154–162). Philadelphia:
Lippincott Williams & Wilkins.
Maxmen, J. S., & Ward, N. G. (2002). Psychotropic drugs:
Fast facts.New York: Norton Publishing.
McIntyre, R. S., McCann, S. M., & Kennedy, S. H. (2001).
Antipsychotic metabolic effects: weight gain, Diabetes
mellitus, and lipid abnormalities. The Canadian
Journal of Psychiatry, 46,273–281.
National Institute of Health. (2000). About ELSI. Re-
trieved 2/3/2002. http://www.nhgri.nhi.gov/ELSI
Ruiz, S., Chu, P., Sramek, J. J., Rotavu, E., & Herrera, J.
(1996). Neuroleptic dosing in Asian and Hispanic
outpatients with schizophrenia. Mt. Sinai Journal of
Medicine, 63(5–6), 306–309.
Sachdev, P. S. (2000). The current status of tardive
dyskinesia. Australian and New Zealand Journal of
Psychiatry, 34,355–369.
Schatzberg, A. F., & Nemeroff, C. B. (2001). Essentials of
clinical psychopharmacology.Washington, DC:
American Psychiatric Publishing.
Selemon, L. D. & Goldman-Rakic, P. S. (1995). Prefrontal
cortex. American Journal of Psychiatry, 152(1), 5.
Shank, R. P., Smith-Swintosky, V. L., & Twyman, R. E.
(2000). Amino acid neurotransmitters. In B. J.
Sadock & V. A. Sadock (Eds.), Comprehensive text-
book of psychiatry, Vol. 1(7th ed., pp. 50–59).
Philadelphia: Lippincott Williams & Wilkins.
Small, G. Genetic risk and imaging.Program and ab-
stracts of the 8th International Conference on
Alzheimer’s Disease and Related Disorders; July
20–25, 2002; Stockholm, Sweden. Abstract 1307.
Sramek, J. J., & Pi, E. H. (1996). Ethnicity and anti-
depressant response. Mt. Sinai Journal of Medicine,
63 (5–6), 320–325.
Stahl, S. M. (2001). Dopamine system stabilizers, arip-
iprazole, and the next generation of antipsychotics:
Goldilocks actions at d receptors. Journal of Clinical
Psychiatry, 62(11), 841–842.
Tecott, L. H. (2000). Monoamine transmitters. In B. J.
Sadock & V. A. Sadock (Eds.), Comprehensive text-
book of psychiatry, Vol. 1(7th ed., pp. 41–50).
Philadelphia: Lippincott Williams & Wilkins.
Valenstein, M., Copeland, L. A., Owne, R., Blow, F. C., &
Visnic, S. (2001). Adherence assessments and the use
of depot antipsychotics in patients with schizophre-
nia. Journal of Clinical Psychiatry, 62(7), 545–551.
Washington, H. (1999). Infection connection. Psychology
Today, 4,43–44, 74–76.
Weiss, E., Hummer, M., Koller, D., Ulmer, H., & Fleisch-
hacker, W. W. (2000). Off-label use of antipsychotic
drugs. Journal of Clinical Psychopharmacology,
20 (6), 695–698.
Woodrum, S. T., & Brown, C. S. (1998). Management of
SSRI-induced sexual dysfunction. The Annals of
Pharmacotherapy, 32,1209–1214.ADDITIONAL READINGS
Hsin-Tung, E., & Simpson, G. M. (2000). Medication-
induced movement disorders. In B. J. Sadock & V. A.
Sadock (Eds.), Comprehensive textbook of psychiatry,
Vol. 2(7th ed., pp. 2265–2271). Philadelphia:
Lippincott Williams & Wilkins.
Mathews, C. A., & Friemer, N. B. (2000). Genetic linkage
analysis of the psychiatric disorders. In B. J. Sadock
& V. A. Sadock (Eds.), Comprehensive textbook of psy-
chiatry, Vol. 1(7th ed., pp. 184–198). Philadelphia:
Lippincott Williams & Wilkins.
Snell, R. S. (1997). Clinical neuroanatomy for medical
students(2d ed.) Philadelphia: Lippincott-Raven.44 Unit 1 CURRENTTHEORIES ANDPRACTICE